Efficacy of long-acting growth hormone in Axenfeld-Rieger syndrome with a novel 3.824 Mb 4q25 deletion: a Case Report and systematic literature review
Frontiers in Genetics · 17.06.2026 · 17
DOI: 10.3389/fgene.2026.1856235 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Genetics, online erschienen am 17.06.2026. Verfasst von Shihui Guan und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Axenfeld-Rieger syndrome (ARS) is a multisystem disorder primarily caused by PITX2 mutations. While eye and dental anomalies are classic, the role of PITX2 as a dosage-sensitive regulator of the human growth axis remains clinically under-recognized. We aim to elucidate the link between large-scale 4q25 microdeletions and severe growth hormone deficiency (GHD).
Methods
A 5.4-year-old boy with ocular segment dysgenesis and short stature underwent family-based whole-exome sequencing (WES). Standardized growth hormone (GH) stimulation tests and longitudinal growth dynamics analysis based on 44 precise clinical data points collected from birth to age 7.45 years were performed. A systematic literature review of 10 ARS cases with growth failure was conducted to propose a pathogenic model.
Results
WES identified a novel de novo 3.824Mb heterozygous deletion at 4q25 (arr[GRCh38] 4q25(108,929,697–112,753,289)×1), encompassing critical genes including CFI , EGF , PITX2 , PANCR , and LARP7 . Our systematic review revealed a dosage-sensitive correlation between the microdeletion scale at the 4q25 region and the severity of growth axis impairment. The patient exhibited complete GHD (peak GH: 4.22 ng/mL) and a 1.5-year bone age delay. Following 20 months of PEG-rhGH therapy, the patient achieved a significant catch-up growth with a cumulative height gain of 16.5 cm, with his height standard deviation score (Ht-SDS) improving from −2.0 SD to within the normal range. Our mechanistic model suggests that PITX2 haploinsufficiency disrupts the POU1F1 (Pit-1) transcriptional cascade, leading to pituitary hypoplasia.
Conclusion
This study reports the one of the most extensive longitudinal follow-up of successful PEG-rhGH therapy in ARS to date. We propose that large 4q25 deletions represent a high-risk genotype for GHD. Mandatory growth monitoring and early endocrine screening are recommended for ARS patients with chromosomal deletions in this region to optimize developmental outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China.
- Diagnosis and Treatment Center for Children, The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China.
Zitieren
APA
Guan, S., Wang, J., Liu, Z., Qi, Y., Sun, X., Jiang, K., & Lin, S. (2026). Efficacy of long-acting growth hormone in Axenfeld-Rieger syndrome with a novel 3.824 Mb 4q25 deletion: a Case Report and systematic literature review. Frontiers in Genetics, 17. https://doi.org/10.3389/fgene.2026.1856235
Vancouver
Guan S, Wang J, Liu Z, Qi Y, Sun X, Jiang K, et al. Efficacy of long-acting growth hormone in Axenfeld-Rieger syndrome with a novel 3.824 Mb 4q25 deletion: a Case Report and systematic literature review. Frontiers in Genetics. 2026;17. doi:10.3389/fgene.2026.1856235
BibTeX
@article{Guan2026,
author = {Guan, Shihui and Wang, Jinyu and Liu, Zhenxian and Qi, Yangfan and Sun, Xiaoyu and Jiang, Kai and Lin, Shuangzhu},
title = {Efficacy of long-acting growth hormone in Axenfeld-Rieger syndrome with a novel 3.824 Mb 4q25 deletion: a Case Report and systematic literature review},
journal = {Frontiers in Genetics},
year = {2026},
volume = {17},
doi = {10.3389/fgene.2026.1856235}
}
EUVIMED